Bosteels Jan, Weyers Steven, D'Hooghe Thomas M, Torrance Helen, Broekmans Frank J, Chua Su Jen, Mol Ben Willem J
Academic Centre for General Practice, Cochrane Belgium, Kapucijnenvoer 33, blok J bus 7001, Leuven, Belgium, 3000.
Cochrane Database Syst Rev. 2017 Nov 27;11(11):CD011110. doi: 10.1002/14651858.CD011110.pub3.
Observational evidence suggests a potential benefit with several anti-adhesion therapies in women undergoing operative hysteroscopy (e.g. insertion of an intrauterine device or balloon, hormonal treatment, barrier gels or human amniotic membrane grafting) for decreasing intrauterine adhesions (IUAs).
To assess the effectiveness of anti-adhesion therapies versus placebo, no treatment or any other anti-adhesion therapy, following operative hysteroscopy for treatment of female subfertility.
We searched the following databases from inception to June 2017: the Cochrane Gynaecology and Fertility Group Specialised Register; the Cochrane Central Register of Studies (CRSO); MEDLINE; Embase; CINAHL and other electronic sources of trials, including trial registers, sources of unpublished literature and reference lists. We handsearched the Journal of Minimally Invasive Gynecology, and we contacted experts in the field. We also searched reference lists of appropriate papers.
Randomised controlled trials (RCTs) of anti-adhesion therapies versus placebo, no treatment or any other anti-adhesion therapy following operative hysteroscopy in subfertile women. The primary outcome was live birth. Secondary outcomes were clinical pregnancy, miscarriage and IUAs present at second-look hysteroscopy, along with mean adhesion scores and severity of IUAs.
Two review authors independently selected studies, assessed risk of bias, extracted data and evaluated quality of evidence using the GRADE method.
The overall quality of the evidence was low to very low. The main limitations were serious risk of bias related to blinding of participants and personnel, indirectness and imprecision. We identified 16 RCTs comparing a device versus no treatment (two studies; 90 women), hormonal treatment versus no treatment or placebo (two studies; 136 women), device combined with hormonal treatment versus no treatment (one study; 20 women), barrier gel versus no treatment (five studies; 464 women), device with graft versus device without graft (three studies; 190 women), one type of device versus another device (one study; 201 women), gel combined with hormonal treatment and antibiotics versus hormonal treatment with antibiotics (one study; 52 women) and device combined with gel versus device (one study; 120 women). The total number of participants was 1273, but data on 1133 women were available for analysis. Only two of 16 studies included 100% infertile women; in all other studies, the proportion was variable or unknown.No study reported live birth, but some (five studies) reported outcomes that were used as surrogate outcomes for live birth (term delivery or ongoing pregnancy). Anti-adhesion therapy versus placebo or no treatment following operative hysteroscopy.There was insufficient evidence to determine whether there was a difference between the use of a device or hormonal treatment compared to no treatment or placebo with respect to term delivery or ongoing pregnancy rates (odds ratio (OR) 0.94, 95% confidence interval (CI) 0.42 to 2.12; 107 women; 2 studies; I² = 0%; very-low-quality evidence).There were fewer IUAs at second-look hysteroscopy using a device with or without hormonal treatment or hormonal treatment or barrier gels compared with no treatment or placebo (OR 0.35, 95% CI 0.21 to 0.60; 560 women; 8 studies; I² = 0%; low-quality evidence). The number needed to treat for an additional beneficial outcome (NNTB) was 9 (95% CI 5 to 17). Comparisons of different anti-adhesion therapies following operative hysteroscopyIt was unclear whether there was a difference between the use of a device combined with graft versus device only for the outcome of ongoing pregnancy (OR 1.48, 95% CI 0.57 to 3.83; 180 women; 3 studies; I² = 0%; low-quality evidence). There were fewer IUAs at second-look hysteroscopy using a device with or without graft/gel or gel combined with hormonal treatment and antibiotics compared with using a device only or hormonal treatment combined with antibiotics, but the findings of this meta-analysis were affected by evidence quality (OR 0.55, 95% CI 0.36 to 0.83; 451 women; 5 studies; I² = 0%; low-quality evidence).
AUTHORS' CONCLUSIONS: Implications for clinical practiceThe quality of the evidence ranged from very low to low. The effectiveness of anti-adhesion treatment for improving key reproductive outcomes or for decreasing IUAs following operative hysteroscopy in subfertile women remains uncertain. Implications for researchMore research is needed to assess the comparative safety and (cost-)effectiveness of different anti-adhesion treatments compared to no treatment or other interventions for improving key reproductive outcomes in subfertile women.
观察性证据表明,几种抗粘连疗法对接受宫腔镜手术的女性(如放置宫内节育器或球囊、激素治疗、屏障凝胶或人羊膜移植)可能有益,可减少宫腔粘连(IUA)。
评估抗粘连疗法与安慰剂、不治疗或任何其他抗粘连疗法相比,在宫腔镜手术后治疗女性不孕症的有效性。
我们检索了以下数据库,时间跨度从数据库建立至2017年6月:Cochrane妇科与生育组专业注册库;Cochrane系统评价数据库(CRSO);医学索引数据库(MEDLINE);荷兰医学文摘数据库(Embase);护理学与健康领域数据库(CINAHL)以及其他试验电子来源,包括试验注册库、未发表文献来源和参考文献列表。我们手工检索了《微创妇科学杂志》,并联系了该领域的专家。我们还检索了相关论文的参考文献列表。
抗粘连疗法与安慰剂、不治疗或任何其他抗粘连疗法在宫腔镜手术后治疗不育女性的随机对照试验(RCT)。主要结局是活产。次要结局是临床妊娠、流产以及二次宫腔镜检查时存在的IUA,以及平均粘连评分和IUA严重程度。
两位综述作者独立选择研究、评估偏倚风险、提取数据并使用GRADE方法评估证据质量。
证据的总体质量为低至极低。主要局限性是与参与者和研究人员的盲法相关的严重偏倚风险、间接性和不精确性。我们纳入了16项RCT,比较了器械与不治疗(两项研究;90名女性)、激素治疗与不治疗或安慰剂(两项研究;136名女性)、器械联合激素治疗与不治疗(一项研究;20名女性)、屏障凝胶与不治疗(五项研究;464名女性)、带移植的器械与不带移植的器械(三项研究;190名女性)、一种器械与另一种器械(一项研究;201名女性)、凝胶联合激素治疗和抗生素与激素治疗加抗生素(一项研究;52名女性)以及器械联合凝胶与器械(一项研究;120名女性)。参与者总数为1273名,但有1133名女性的数据可用于分析。16项研究中只有两项纳入了100%的不孕女性;在所有其他研究中,该比例各不相同或未知。没有研究报告活产情况,但一些研究(五项研究)报告了用作活产替代结局的结果(足月分娩或持续妊娠)。宫腔镜手术后抗粘连疗法与安慰剂或不治疗的比较。没有足够的证据来确定在足月分娩或持续妊娠率方面,使用器械或激素治疗与不治疗或安慰剂相比是否存在差异(优势比(OR)0.94,95%置信区间(CI)0.42至2.12;107名女性;两项研究;I² = 0%;极低质量证据)。与不治疗或安慰剂相比,使用带或不带激素治疗的器械、激素治疗或屏障凝胶在二次宫腔镜检查时的IUA较少(OR 0.35,95%CI 0.21至0.60;560名女性;八项研究;I² = 0%;低质量证据)。额外有益结局的治疗所需人数(NNTB)为9(95%CI 5至17)。宫腔镜手术后不同抗粘连疗法的比较。对于持续妊娠结局,使用带移植的器械与仅使用器械之间是否存在差异尚不清楚(OR 1.48,95%CI 0.57至3.83;180名女性;三项研究;I² = 0%;低质量证据)。与仅使用器械或激素治疗加抗生素相比,使用带或不带移植/凝胶的器械或凝胶联合激素治疗和抗生素在二次宫腔镜检查时的IUA较少,但该荟萃分析的结果受证据质量影响(OR 0.55,95%CI 0.36至0.83;451名女性;五项研究;I² = 0%;低质量证据)。
对临床实践的启示证据质量从极低到低不等。抗粘连治疗在改善关键生殖结局或减少宫腔镜手术后不育女性的IUA方面的有效性仍不确定。对研究的启示需要更多研究来评估不同抗粘连治疗与不治疗或其他干预措施相比,在改善不育女性关键生殖结局方面的相对安全性和(成本 - )效益。